Citadel Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
Other funds holding IDNA
WBG
PGA
CCA
Citadel Advisors's IDNA Position: Q1 2026 in Review
Citadel Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2026, closing a stake of 11,490 shares — an estimated $301K sold.
Citadel Advisors first reported a position in IDNA in Q2 2020 and held it in 16 quarters. The position peaked at $3.66M in Q4 2021. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.
- Citadel Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 11,490 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $301K.
- Citadel Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and held it in 16 quarters.
- Citadel Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $3.66M in Q4 2021.
- 60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.